← Back to Search

Group 1:With CCX872-B for Pancreatic Cancer

Phase 1 & 2
Waitlist Available
Research Sponsored by Alan Katz
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 years
Awards & highlights

Study Summary

Standard treatment for newly diagnosed operable pancreatic cancer usually involves undergoing surgery first and then receiving chemotherapy with or without radiation therapy. However, the pancreatic cancer often comes back after this treatment. Therefore, the investigators are studying whether giving treatment prior to surgery can help decrease the risk the cancer returns. Stereotactic Body Radiation Therapy (SBRT) is a highly focused type of radiation therapy commonly used in the treatment of pancreatic cancer. This treatment has been shown to be safe and effective for the preoperative treatment of pancreatic cancer. The purpose of this study is to determine if combining an experimental drug, CCX872-B, with SBRT continues to be safe and whether the combination treatment may be more effective at boosting the participant's immune system's ability to kill the pancreatic cancer.

Eligible Conditions
  • Pancreatic Cancer
  • Pancreatic Adenocarcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of patients who are ineligible for surgical resection due to toxicity from SBRT + CCX872-B or SBRT alone
Percentage of patients who complete radiation therapy, drug treatment and surgery
Secondary outcome measures
Mean time to death
Mean time to progression of pancreatic cancer
Number of participants with no further growth of cancer at original site
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Group 1:With CCX872-BExperimental Treatment1 Intervention
Concurrent SBRT 25 Gy in 5 fractions over 5-7 days, and 21 days of CCX872-B therapy. CCX872-B 150 mg by mouth twice daily approximately 12 hours apart.
Group II: Group 2:Without CCX872-BActive Control1 Intervention
SBRT Alone: 25 Gy in 5 fractions over 5-7 days
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CCX872-B
2015
Completed Phase 1
~60

Find a Location

Who is running the clinical trial?

Alan KatzLead Sponsor
1 Previous Clinical Trials
56 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B
Alan Katz 2019. "Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03778879.
~0 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top